Coherus Biosciences
Coherus Biosciences is a biopharmaceutical company dedicated to the development, manufacture, and commercialization of biologic therapeutics, primarily targeting oncology and inflammatory diseases. The company emphasizes process science, analytical characterization, protein production, and clinical-regulatory development. Its product portfolio includes various FDA-approved therapeutics, such as UDENYCA, a biosimilar of Neulasta, and YUSIMRY, an FDA-approved Humira biosimilar anticipated for launch in 2023. Coherus is also building an immuno-oncology franchise, supported by revenue generated from its diverse portfolio of approved products. The company is actively engaged in developing biosimilar candidates across immunology, ophthalmology, and oncology, aiming to enhance treatment options for patients.
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.